CGRP receptor antagonists: A new frontier of anti-migraine medications

7Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Migraine is a chronic pain condition that affects 12% of the population. Currently, the most effective treatments are the triptans, but they are limited in their efficacy and have potentially deleterious cardiovascular complications. On the basis of basic science studies over the past decade, a new generation of anti-migraine drugs is now being developed. At the forefront of these studies is a new calcitonin gene-related peptide (CGRP) receptor antagonist that is as effective as triptans in the acute treatment of migraines, without the cardiovascular effects. This review will address the likely mechanisms and therapeutic potential of CGRP receptor antagonists. © 2006 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

de Prado, B. M., & Russo, A. F. (2006, June). CGRP receptor antagonists: A new frontier of anti-migraine medications. Drug Discovery Today: Therapeutic Strategies. https://doi.org/10.1016/j.ddstr.2006.11.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free